HC Wainwright Has Pessimistic Outlook of HRMY Q2 Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Equities research analysts at HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for Harmony Biosciences in a research note issued on Wednesday, May 7th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of $0.87 per share for the quarter, down from their prior estimate of $0.90. HC Wainwright currently has a "Buy" rating and a $70.00 target price on the stock. The consensus estimate for Harmony Biosciences' current full-year earnings is $2.43 per share.

A number of other research analysts have also weighed in on the company. Deutsche Bank Aktiengesellschaft assumed coverage on Harmony Biosciences in a report on Tuesday, February 11th. They set a "buy" rating and a $55.00 price objective on the stock. Needham & Company LLC restated a "buy" rating and issued a $49.00 price objective on shares of Harmony Biosciences in a research report on Tuesday, May 6th. Mizuho increased their target price on Harmony Biosciences from $42.00 to $44.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 18th. Finally, UBS Group reduced their target price on Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating on the stock in a research report on Monday, April 28th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $52.33.

Harmony Biosciences Stock Performance

HRMY stock traded down $0.98 during trading on Monday, hitting $33.39. The company had a trading volume of 685,299 shares, compared to its average volume of 591,222. The firm has a market cap of $1.92 billion, a PE ratio of 15.82, a price-to-earnings-growth ratio of 0.47 and a beta of 0.82. Harmony Biosciences has a 1-year low of $26.47 and a 1-year high of $41.61. The firm has a 50-day moving average price of $31.43 and a 200-day moving average price of $34.02. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.59 by $0.19. The business had revenue of $184.73 million for the quarter, compared to analysts' expectations of $184.26 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The business's revenue was up 19.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.67 earnings per share.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of HRMY. Hillsdale Investment Management Inc. increased its holdings in shares of Harmony Biosciences by 0.4% during the 4th quarter. Hillsdale Investment Management Inc. now owns 68,000 shares of the company's stock valued at $2,340,000 after acquiring an additional 300 shares during the last quarter. Aurora Investment Counsel grew its holdings in Harmony Biosciences by 0.6% in the 1st quarter. Aurora Investment Counsel now owns 61,667 shares of the company's stock valued at $2,047,000 after buying an additional 374 shares during the last quarter. O Shaughnessy Asset Management LLC grew its holdings in Harmony Biosciences by 2.1% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 20,450 shares of the company's stock valued at $704,000 after buying an additional 420 shares during the last quarter. GAMMA Investing LLC grew its holdings in Harmony Biosciences by 92.6% in the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company's stock valued at $31,000 after buying an additional 436 shares during the last quarter. Finally, Rhumbline Advisers grew its holdings in Harmony Biosciences by 0.4% in the 1st quarter. Rhumbline Advisers now owns 109,073 shares of the company's stock valued at $3,620,000 after buying an additional 485 shares during the last quarter. 86.23% of the stock is owned by institutional investors and hedge funds.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.